<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-19431" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Chlamydia</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Mohseni</surname>
            <given-names>Michael</given-names>
          </name>
          <aff>Mayo Clinic</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Sung</surname>
            <given-names>Sharon</given-names>
          </name>
          <aff>Sparrow Hospital</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Takov</surname>
            <given-names>Veronica</given-names>
          </name>
          <aff>McLaren Macomb Regional Medical Center</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Michael Mohseni declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Sharon Sung declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Veronica Takov declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>8</day>
          <month>8</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-19431.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Chlamydia trachomatis is responsible for the greatest number of sexually transmitted infections and the majority of infection-related of blindness worldwide. In the United States, it is the most commonly reported bacterial infection. This activity reviews the evaluation and management of Chlamydia trachomatis infections and highlights the role of the interprofessional team in the care of affected patients.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Describe the global incidence and prevalence of chlamydia trachomatis.</p></list-item><list-item><p>Describe the common presentations of chlamydia trachomatis infections.</p></list-item><list-item><p>Describe the appropriate treatment of chlamydia trachomatis infections.</p></list-item><list-item><p>Explain the importance of enhancing care coordination amongst the interprofessional team to improve outcomes for patients with chlamydia trachomatis infections.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=19431&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=19431">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-19431.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Chlamydia is a sexually transmitted infectious disease caused by the bacterium <italic toggle="yes">Chlamydia trachomatis</italic>. In the United States, it is the most commonly reported bacterial infection. Globally, it is the most common sexually transmitted infection.&#x000a0;It causes an ocular infection called "trachoma," which is the leading infectious cause of blindness worldwide.</p>
        <p>In females, the cervix is the anatomic site that is most commonly infected. This can manifest as cervicitis, urethritis, pelvic inflammatory disease, perihepatitis, or proctitis. Chlamydial infections in women, especially if untreated, increase the risk of infertility and ectopic pregnancy, leading to&#x000a0;high medical costs.<xref ref-type="bibr" rid="article-19431.r1">[1]</xref> There are also risks if a woman has an infection during pregnancy. Additionally, infants born vaginally to mothers infected with genital <italic toggle="yes">Chlamydia trachomatis</italic> may develop conjunctivitis and/or pneumonia.&#x000a0;&#x000a0;</p>
        <p>In men, infection with <italic toggle="yes">Chlamydia trachomatis </italic>can lead to urethritis, epididymitis, prostatitis, proctitis, or reactive arthritis. Both men and women infected with <italic toggle="yes">C. trachomatis</italic> may also experience conjunctivitis, pharyngitis, and lymphogranuloma venereum. Lymphogranuloma venereum (LGV), caused by distinct serovars of <italic toggle="yes">Chlamydia trachomatis</italic>, is a less common disease characterized by enlarged lymph nodes or severe proctocolitis.<xref ref-type="bibr" rid="article-19431.r2">[2]</xref></p>
      </sec>
      <sec id="article-19431.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p><italic toggle="yes">Chlamydia trachomatis</italic> is part of the <italic toggle="yes">chlamydophila</italic> genus. These bacteria are gram-negative, anaerobic, intracellular obligates that replicate within eukaryotic&#x000a0;cells.&#x000a0;<italic toggle="yes">C.&#x000a0;trachomatis</italic> differentiates into 18 serovars (serologically variant strains) based on monoclonal antibody-based typing assays. These serovars correlate with multiple medical conditions&#x000a0;as follows<xref ref-type="bibr" rid="article-19431.r3">[3]</xref>:</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Serovars A, B, Ba, and C:</bold> Trachoma is a serious ocular illness that is endemic in Africa and Asia. It is characterized by chronic conjunctivitis and has the potential to cause blindness</p>
          </list-item>
          <list-item>
            <p><bold>Serovars D-K:</bold> Genital tract infections, neonatal infections</p>
          </list-item>
          <list-item>
            <p><bold>Serovars L1-L3:</bold> Lymphogranuloma venereum (LGV), which correlates with genital ulcer disease in tropical countries.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-19431.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Urogenital chlamydia infections are the most commonly reported bacterial infections in the U.S and the most common cause of sexually transmitted&#x000a0;infections in the world. The overall rate of urogenital infection amongst U.S. women is two times that of U.S. men, with a higher prevalence in women 15-24 years of age and a higher incidence in men between 20-24 years of age.</p>
      </sec>
      <sec id="article-19431.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p><italic toggle="yes">Chlamydia</italic> is unique among bacteria, having an infectious cycle and two developmental forms. These include the infectious form called the elementary body (EB) and the reticulate body (RB). The EB is metabolically inactive and is taken up by host cells. Within the host cell, the EB will differentiate into the metabolically active RB. The RB will then use host energy sources and amino acids to replicate and form new EB, which can then infect additional cells. <italic toggle="yes">C. trachomatis</italic> targets the squamocolumnar epithelial cells of the endocervix and upper genital tract in women, and the conjunctiva, urethra, and rectum in both men and women.&#x000a0;</p>
        <p>The bacterium is transmitted through direct contact with infected tissue, including vaginal, anal, or oral sex, and can even be passed from an infected mother to the newborn during childbirth.</p>
      </sec>
      <sec id="article-19431.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>Typical intracytoplasmic inclusions and free chlamydiae are identifiable in Giemsa-stained cell scrapings from the eye. Stained conjunctival scrapings are positive in 90% of infants with neonatal conjunctivitis, and 50% of adults with inclusion conjunctivitis. Cytology techniques can be used&#x000a0;to evaluate endocervical scrapings, but the sensitivity and specificity are low.<xref ref-type="bibr" rid="article-19431.r4">[4]</xref></p>
      </sec>
      <sec id="article-19431.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p><italic toggle="yes">C. trachomatis</italic> can lead to many urogenital infections, including&#x000a0;cervicitis, pelvic inflammatory disease, urethritis, epididymitis, prostatitis, and lymphogranuloma venereum. Extragenital infections caused by <italic toggle="yes">C. trachomatis</italic> include conjunctivitis, perihepatitis, pharyngitis, reactive arthritis, and proctitis.&#x000a0;</p>
        <p>More frequently, patients remain asymptomatic reservoirs of the disease. In the minority of patients who become symptomatic, clinical signs depend on the location of the infection. Below are the common signs and symptoms associated with <italic toggle="yes">C. trachomatis</italic> urogenital infections.</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Cervicitis:</bold> Approximately 70% of women will be asymptomatic or have mild symptoms such as vaginal discharge, bleeding, abdominal pain, and dysuria.<xref ref-type="bibr" rid="article-19431.r5">[5]</xref> Only a minority of women have the classic presentation of mucopurulent cervicitis with discharge and easily-induced endocervical bleeding. Some women may complain of postcoital bleeding or intermenstrual bleeding.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Pelvic Inflammatory Disease:</bold> This occurs when <italic toggle="yes">C.&#x000a0;trachomatis</italic> ascends to the upper reproductive tract. Most commonly, these patients will have abdominal or pelvic pain with or without signs and symptoms of cervicitis. Other symptoms include nausea, vomiting, fevers, chills, low back pain, pain with intercourse, dysuria, or postcoital bleeding. <xref ref-type="bibr" rid="article-19431.r6">[6]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Urethritis:</bold> It is most commonly seen in men. There are subtle clinical differences between gonococcal urethritis and chlamydial urethritis, but making a reliable distinction without testing is not possible. It presents with dysuria and urethral discharge, which is typically white, gray, or sometimes clear, and may only be evident after penile "stripping" or during morning hours. Women with urethritis may complain of frequency or dysuria and may mistake their symptoms for a urinary tract infection. Urinalysis will reveal pyuria, but neither bacterial culture nor gram stain will reveal organisms.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Perihepatitis:</bold> Also called Fitz-Hugh-Curtis syndrome, this syndrome occurs when chlamydia infection leads to inflammation of the liver capsule and the peritoneal surfaces nearby. This syndrome is most commonly seen in patients who have a pelvic inflammatory disease, and it is associated with right upper quadrant or pleuritic pain. Unlike other conditions that may affect the liver or cause right upper quadrant pain, abnormalities in liver enzymes are not typically found.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Epididymitis:</bold> Typically, men will present with unilateral testicular pain and tenderness, possible hydrocele, palpable swelling of the epididymis, and fever.&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Proctitis:</bold> Rectal infection with chlamydia can be asymptomatic if caused by genital serovars D through K. However, if LGV serovars L1-L3 are the cause of proctitis, patients may complain of rectal pain, discharge, and bleeding in the setting of receptive anal intercourse. Patients may also present with a fever or malaise. This is seen almost exclusively in males who have sex with males; however, anal intercourse is not uncommon in heterosexual intercourse.&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Prostatitis:</bold> Symptoms include dysuria, urinary dysfunction, pelvic pain, and pain with ejaculation. Expressed secretions from the prostate may show increased leukocytes on microscopy.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Reactive Arthritis:</bold> Approximately 1% of men who have urethritis from chlamydial infection also develop reactive arthritis, and a third will have the reactive arthritis triad (formerly known as Reiter syndrome).<xref ref-type="bibr" rid="article-19431.r7">[7]</xref> The triad consists of arthritis, urethritis, and uveitis.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Conjunctivitis:</bold> Direct inoculation with genital secretions infected with genital <italic toggle="yes">Chlamydia trachomatis</italic> serovars can lead to conjunctival infection. Symptoms typically include non-purulent conjunctivitis (erythematous injection of the surface epithelium). The conjunctiva may have a cobbled appearance. Conjunctivitis is the most common manifestation of chlamydial infection in newborns.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Pneumonia:</bold> Infants born to mothers who have a cervical infection with <italic toggle="yes">Chlamydia trachomatis</italic> may develop pneumonia 5-30% of the time.<xref ref-type="bibr" rid="article-19431.r8">[8]</xref> Recognition usually occurs between 4 to 12 weeks of age, though almost all infants have symptoms before eight weeks. Nasal congestion and cough are common, and some infants may have thick nasal secretions.<xref ref-type="bibr" rid="article-19431.r9">[9]</xref> Infants usually have no fever or only a minimal fever, they may have tachypnea, and they may have a characteristic paroxysmal staccato cough. In preterm infants, apneic spells may be seen. Rales may be heard on auscultation of the lungs, but wheezing is uncommon.&#x000a0;&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Pharyngitis:</bold> While not considered a significant cause of pharyngitis, <italic toggle="yes">C. trachomatis</italic> can be detected in the pharynx with nucleic acid amplified tests.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Lymphogranuloma Venereum:</bold> Patients will present with painless genital ulcers. The ulcers typically have a small, stellate appearance. The development of inguinal lymphadenopathy typically follows the appearance of ulcers.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-19431.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Among <italic toggle="yes">C. trachomatis</italic> infections, the only&#x000a0;trachoma is diagnosable on clinical grounds. Other chlamydial infections are associated&#x000a0;with specific clinical syndromes but require laboratory confirmation. The gold standard for the diagnosis of urogenital chlamydia infections is nucleic acid amplification testing (NAAT). This test is run on either the vaginal swabs for women or first-catch urine for men. Testing can also be performed on endocervical or urethral swabs. Swabs should have a wire or plastic shaft; the tip should be dacron or rayon or a cytobrush. Other materials may inhibit <italic toggle="yes">Chlamydia trachomatis</italic>. Alternative methods of testing include culture, rapid testing, serology, antigen detection, and genetic probes. If there is no testing available, treatment is recommended based on clinical presentation.</p>
        <p>When a patient presents with suspected chlamydia infection, a workup for other STDs should be carried out. A complete blood count is essential if PID is suspected. One may consider testing for HIV, gonorrhea, and syphilis. The sexual partner must be tested for chlamydia. A pregnancy test should be done as it is a contraindication to doxycycline therapy.</p>
        <p>Cytology is often used in patients with conjunctivitis and ocular trachoma. Cultures are usually not done for chlamydia as the organism is difficult to grow in the laboratory. However, in patients with anal and rectal involvement, cultures are ideal as other tests are difficult to interpret.</p>
        <p>The&#x000a0;United States Preventive Services Task Force (USPSTF) recommends regular screening for chlamydia in all sexually active women because if left untreated, the infection is associated with PID, infertility, and chronic pelvic pain. In males, the leucocyte esterase test in urine can be done and is diagnostic for gonorrhea or chlamydia in the absence of a UTI.</p>
      </sec>
      <sec id="article-19431.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>The goal of treatment is the prevention of complications associated with infection (e.g., PID, infertility), to decrease the risk of transmission, and the resolution of symptoms. Treatment for uncomplicated urogenital chlamydia infection is with azithromycin. Doxycycline is an alternative, but azithromycin is preferred as it is a single-dose therapy. Other alternatives include erythromycin, levofloxacin, and ofloxacin.</p>
        <p>Chlamydial infection and gonococcal infections often coexist. In men, the co-treatment for urogenital gonococcal infection should occur on the basis of the detection of the organism on NAAT or gram stain. In women, the gram stain is less helpful due to the possibility of normal <italic toggle="yes">Neisseria</italic> species colonization within the vaginal flora. Therefore, co-treatment should be dependent on an assessment of individual patient risk and local prevalence rates.</p>
        <p>Patients should have partners identified and tested. They should also be counseled on high-risk behaviors, avoid sexual activity for one week after initiating therapy, and should consider testing&#x000a0;for HIV.</p>
        <p>Verification of cure should occur three weeks after treatment completion, and&#x000a0;retesting should be performed three months after treatment.</p>
        <p>If symptoms persist after treatment, consider coinfection with a secondary bacterium or reinfection.</p>
        <p>Follow up culture is not recommended in most people but may be considered in a pregnant female. <xref ref-type="bibr" rid="article-19431.r10">[10]</xref><xref ref-type="bibr" rid="article-19431.r11">[11]</xref><xref ref-type="bibr" rid="article-19431.r12">[12]</xref><xref ref-type="bibr" rid="article-19431.r11">[11]</xref><xref ref-type="bibr" rid="article-19431.r10">[10]</xref></p>
      </sec>
      <sec id="article-19431.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Because Chlamydia trachomatis can lead to a broad spectrum of clinical diseases or manifestations, the differential diagnosis of various presenting complaints is also broad. One should consider other etiologies that may affect each body area or organ systems and may manifest similarly.&#x000a0;</p>
        <p>Dysuria:</p>
        <list list-type="bullet">
          <list-item>
            <p>Gonorrhea</p>
          </list-item>
          <list-item>
            <p>Genital herpes</p>
          </list-item>
          <list-item>
            <p>Urinary tract infection</p>
          </list-item>
        </list>
        <p>Abdominal Pain:</p>
        <list list-type="bullet">
          <list-item>
            <p>Appendicitis</p>
          </list-item>
          <list-item>
            <p>Cholecystitis</p>
          </list-item>
          <list-item>
            <p>Constipation</p>
          </list-item>
        </list>
        <p>Pelvic Pain:</p>
        <list list-type="bullet">
          <list-item>
            <p>Endometriosis</p>
          </list-item>
          <list-item>
            <p>Ovarian cysts</p>
          </list-item>
          <list-item>
            <p>Adenomyosis</p>
          </list-item>
        </list>
        <p>Vaginal Discharge:</p>
        <list list-type="bullet">
          <list-item>
            <p>Bacterial vaginosis</p>
          </list-item>
          <list-item>
            <p>
<italic toggle="yes">Trichomonas vaginalis</italic>
</p>
          </list-item>
          <list-item>
            <p>Gonorrhea</p>
          </list-item>
          <list-item>
            <p>Vaginal candidiasis</p>
          </list-item>
          <list-item>
            <p>Foreign body</p>
          </list-item>
          <list-item>
            <p><italic toggle="yes">Mycoplasma genitalium</italic> infection</p>
          </list-item>
          <list-item>
            <p><italic toggle="yes">Ureaplasma</italic> infection</p>
          </list-item>
        </list>
        <p>Rectal Discharge:</p>
        <list list-type="bullet">
          <list-item>
            <p>Inflammatory bowel disease</p>
          </list-item>
          <list-item>
            <p>Gonorrhea</p>
          </list-item>
        </list>
        <p>Conjunctivitis:</p>
        <list list-type="bullet">
          <list-item>
            <p>Viral infection</p>
          </list-item>
          <list-item>
            <p>Allergy</p>
          </list-item>
          <list-item>
            <p>Gonococcal infection</p>
          </list-item>
        </list>
        <p>Postcoital or Intermenstrual Bleeding:</p>
        <list list-type="bullet">
          <list-item>
            <p>Cervical cancer</p>
          </list-item>
          <list-item>
            <p>Cervical or endometrial polyp</p>
          </list-item>
          <list-item>
            <p>Cervical ectropion</p>
          </list-item>
          <list-item>
            <p>Leiomyoma</p>
          </list-item>
          <list-item>
            <p>Pregnancy</p>
          </list-item>
        </list>
        <p>Genital Ulceration:</p>
        <list list-type="bullet">
          <list-item>
            <p>Herpes simplex</p>
          </list-item>
          <list-item>
            <p>Syphilis</p>
          </list-item>
          <list-item>
            <p>Chancroid</p>
          </list-item>
          <list-item>
            <p>Granuloma inguinale</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-19431.s11" sec-type="Treatment Planning ">
        <title>Treatment Planning </title>
        <p>Uncomplicated Genital Chlamydia:</p>
        <p>The World Health Organization (WHO) recommendations for treatment of uncomplicated genital chlamydia infections are the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Azithromycin 1000 mg orally as a single dose&#x000a0;<bold>or</bold></p>
          </list-item>
          <list-item>
            <p>Doxycycline 100 mg orally twice a day for seven days, or one of these alternatives: tetracycline 500 mg by mouth four times a day for seven days, erythromycin 500 mg orally twice daily for 7 days, or ofloxacin 200-400 mg orally twice daily for 7 days</p>
          </list-item>
        </list>
        <p>Anorectal Chlamydial infection:</p>
        <p>In anorectal chlamydial infections, the WHO recommendation is oral doxycycline 100 mg twice daily for 7 days over oral azithromycin 1 g as a single dose.</p>
        <p>Chlamydial infection in pregnancy:</p>
        <p>WHO recommends the following for the treatment of chlamydial infection in pregnancy:</p>
        <list list-type="bullet">
          <list-item>
            <p>Azithromycin recommended over erythromycin, amoxicillin, and erythromycin</p>
          </list-item>
          <list-item>
            <p>Azithromycin 1 g orally as a single dose&#x000a0;<bold>or</bold></p>
          </list-item>
          <list-item>
            <p>Amoxicillin 500 mg orally three times daily for 7 days&#x000a0;<bold>or</bold></p>
          </list-item>
          <list-item>
            <p>Erythromycin 500 mg orally twice daily for 7 days</p>
          </list-item>
        </list>
        <p>Lymphogranuloma Venereum:</p>
        <p>The WHO recommends the following for the treatment of lymphogranuloma venereum (LGV):</p>
        <list list-type="bullet">
          <list-item>
            <p>In adults and adolescents with lymphogranuloma venereum, the guidelines suggest doxycycline 100 mg orally twice a day for 21 days over azithromycin 1 g orally weekly for 3 weeks.</p>
          </list-item>
          <list-item>
            <p>Good practice dictates the treatment of LGV, particularly for men who have sex with men and for people with HIV infection.</p>
          </list-item>
          <list-item>
            <p>When contraindications to doxycycline are present, azithromycin should be the therapeutic choice.</p>
          </list-item>
          <list-item>
            <p>When no other treatment options are available, erythromycin 500 mg orally four times a day for 21 days is an alternative.</p>
          </list-item>
          <list-item>
            <p>Doxycycline should not be used in pregnancy.</p>
          </list-item>
        </list>
        <p>Infant disease:</p>
        <p>Oral erythromycin is the preferred treatment for both conjunctivitis and pneumonia in the neonate. Azithromycin is an acceptable alternative. Infants who fail an initial course of erythromycin are recommended to retreat with another fourteen-day course of erythromycin.</p>
        <list list-type="bullet">
          <list-item>
            <p>Erythromycin 50 mg/kg by mouth in 4 divided doses for 14 days <bold>or</bold></p>
          </list-item>
          <list-item>
            <p>Azithromycin 20 mg/kg by mouth daily for 3 days</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-19431.s12" sec-type="Toxicity and Adverse Effect Management">
        <title>Toxicity and Adverse Effect Management</title>
        <p>In neonates being treated for chlamydial infection, both azithromycin and erythromycin are associated with a risk of infantile hypertrophic pyloric stenosis. This is particularly a concern for infants two weeks old or younger. Parents and physicians should observe infants closely for any signs of intestinal obstruction.</p>
      </sec>
      <sec id="article-19431.s13" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Antibiotic treatment has a 95% effectiveness rate for first-time therapy. The prognosis is excellent with prompt initiation of treatment early and with the completion of the entire course of antibiotics. Although treatment failures with primary therapies are quite rare, relapse may occur. Reinfection is common and is usually related to the nontreatment of infected sexual partners or acquisition from a new partner. Death is rare but can be&#x000a0;caused by progression to salpingitis and tubo-ovarian abscess with rupture and peritonitis. The most significant morbidity occurs with repetitive infection with chlamydiae, which leads to scarring of the fallopian tubes and subsequent sterility.</p>
      </sec>
      <sec id="article-19431.s14" sec-type="Complications">
        <title>Complications</title>
        <p>Pelvic inflammatory disease confers a risk of ectopic pregnancy in women of childbearing age. Inflammation and scarring of the upper genital tract may also affect fertility or lead to chronic pelvic pain. Chlamydial infection in pregnancy can also increase the risk of prelabour rupture of membranes (PROM), premature prelabour rupture of membranes (PPROM), and preterm delivery.<xref ref-type="bibr" rid="article-19431.r13">[13]</xref></p>
      </sec>
      <sec id="article-19431.s15" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Asymptomatic infection with <italic toggle="yes">Chlamydia trachomatis</italic> is very common, whereas the consequences of undiagnosed or untreated infection can be far-reaching. It is for these reasons that screening is recommended. All pregnant women are recommended to be screened for <italic toggle="yes">C. trachomatis</italic>. All sexually active females younger than 25 should be screened annually. Women older than 25 should be screened if they have risk factors for sexually transmitted infections. Risk factors include sexual partners with multiple concurrent partners, new or multiple sexual partners, inconsistent use of condoms if the relationship is not monogamous, exchanging sex for money or drugs, or previous/coexisting STI. Men who have sex with men should also be screened for chlamydial infection. In individuals with HIV, screening should be done at the initial presentation and annually. For individuals entering a correctional facility, it is recommended to screen for chlamydia in women 35 years old or younger and men thirty years old or younger.&#x000a0;</p>
        <p>In the United States, <italic toggle="yes">C. trachomatis</italic> is considered a notifiable infection. Local and state laws regarding disease reporting apply. Sexual partners should be notified, examined, and treated if an STI is found in the index patient. Expedited partner therapy may also be available in certain settings. Expedited partner therapy allows providers to prescribe antibiotics to sexual contacts without establishing a physician-patient relationship.</p>
        <p>Patients should be educated regarding the potentially serious consequences of chlamydia infections and the importance of screening. Patients also should be educated that screening can often be performed non-invasively with urine samples. Educated patients may then be agreeable to screening when they would otherwise hesitate out of fear of an uncomfortable exam.</p>
      </sec>
      <sec id="article-19431.s16" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>In the United States and other developed countries, the prevention of sexually transmitted genital infections and complications mainly focuses on screening and treating nonpregnant sexually active women aged 25 years or younger on an annual basis. Screening for pregnant women is recommended, and screening and treatment of women over&#x000a0;25 years of age are recommendations if there are identifiable risk factors, such as new or multiple sexual partners. Screening of young men in high-risk settings (sexually transmitted&#x000a0;infection and adolescent clinics,&#x000a0;correctional&#x000a0;facilities) should be a consideration if resources allow. Urine or endocervical&#x000a0;NAAT&#x000a0;are the recommended screening tests. The&#x000a0;partner should be screened and treated at the same time.</p>
        <p>Healthcare workers and nurse practitioners should educate patients on the importance of using a condom during sex, practicing safe sex or abstaining from sexual activity to prevent chlamydia.</p>
        <p>Pharmacists should verify dosing and agent selection for antimicrobial therapy, check for drug interactions, and report any concerns to the prescriber.</p>
        <p>The prognosis is excellent with prompt initiation of treatment early, and with the completion of the entire course of antibiotics, antibiotic treatment is 95% effective for first-time therapy.</p>
        <p>No vaccine is currently&#x000a0;available for either trachoma or chlamydial genital infections.&#x000a0;</p>
        <p>The healthcare team, including clinicians, nurses, and pharmacists, must work together to educate the patient on methods to avoid exposure and the importance of completing treatment. This approach will result in decreased incidence and improve outcomes. [Level 5]</p>
      </sec>
      <sec id="article-19431.s17">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=19431&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=19431">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/sexual-health/chlamydia/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=19431">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/19431/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=19431">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-19431.s18">
        <fig id="article-19431.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Alpha-1 Antitrypsin Deficiency in Emphysema, Transmission Electron Microscopy. Chlamydial bodies are shown by arrows; also seen is the destruction of the interstitial connective tissue, with the ultrastructure less well preserved after the fixation of formaldehyde. Theegarten D, Anhenn O, Hotzel H, et al. A comparative ultrastructural and molecular biological study on <italic toggle="yes">Chlamydia psittaci</italic> infection in alpha-1 antitrypsin deficiency and non-alpha-1 antitrypsin deficiency emphysema versus lung tissue of patients with hamartochondroma. <italic toggle="yes">BMC Infect Dis</italic>. 2004;4:38. doi: 10.1186/1471-2334-4-38.&#x000a0;</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="1471-2334-4-38-4" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-19431.s19">
        <fig id="article-19431.image.f2" position="float" orientation="portrait">
          <caption>
            <p>Follicular Conjunctivitis.&#x000a0;Inflammation is noted with viral infections like herpes zoster, Epstein-Barr virus infection, infectious mononucleosis, and chlamydial infections, as well as in reaction&#x000a0;to topical medications and molluscum contagiosum. Follicular conjunctivitis has been described in patients with COVID-19. The inferior and superior tarsal conjunctiva and the fornices show gray-white elevated swellings about 0.5 to 1 mm in diameter and have a velvety appearance. Contributed by Prof. BCK Patel MD, FRCS</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Follicular__conjunctivitis-BCK__Patel__MD" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-19431.s20">
        <title>References</title>
        <ref id="article-19431.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Owusu-Edusei</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Chesson</surname>
                <given-names>HW</given-names>
              </name>
              <name>
                <surname>Gift</surname>
                <given-names>TL</given-names>
              </name>
              <name>
                <surname>Tao</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Mahajan</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ocfemia</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Kent</surname>
                <given-names>CK</given-names>
              </name>
            </person-group>
            <article-title>The estimated direct medical cost of selected sexually transmitted infections in the United States, 2008.</article-title>
            <source>Sex Transm Dis</source>
            <year>2013</year>
            <month>Mar</month>
            <volume>40</volume>
            <issue>3</issue>
            <fpage>197</fpage>
            <page-range>197-201</page-range>
            <pub-id pub-id-type="pmid">23403600</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19431.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mabey</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Peeling</surname>
                <given-names>RW</given-names>
              </name>
            </person-group>
            <article-title>Lymphogranuloma venereum.</article-title>
            <source>Sex Transm Infect</source>
            <year>2002</year>
            <month>Apr</month>
            <volume>78</volume>
            <issue>2</issue>
            <fpage>90</fpage>
            <page-range>90-2</page-range>
            <pub-id pub-id-type="pmid">12081191</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19431.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Morr&#x000e9;</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Rozendaal</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>van Valkengoed</surname>
                <given-names>IG</given-names>
              </name>
              <name>
                <surname>Boeke</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>van Voorst Vader</surname>
                <given-names>PC</given-names>
              </name>
              <name>
                <surname>Schirm</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>de Blok</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>van Den Hoek</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>van Doornum</surname>
                <given-names>GJ</given-names>
              </name>
              <name>
                <surname>Meijer</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>van Den Brule</surname>
                <given-names>AJ</given-names>
              </name>
            </person-group>
            <article-title>Urogenital Chlamydia trachomatis serovars in men and women with a symptomatic or asymptomatic infection: an association with clinical manifestations?</article-title>
            <source>J Clin Microbiol</source>
            <year>2000</year>
            <month>Jun</month>
            <volume>38</volume>
            <issue>6</issue>
            <fpage>2292</fpage>
            <page-range>2292-6</page-range>
            <pub-id pub-id-type="pmid">10834991</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19431.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mordhorst</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Dawson</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Sequelae of neonatal inclusion conjunctivitis and associated disease in parents.</article-title>
            <source>Am J Ophthalmol</source>
            <year>1971</year>
            <month>Apr</month>
            <volume>71</volume>
            <issue>4</issue>
            <fpage>861</fpage>
            <page-range>861-7</page-range>
            <pub-id pub-id-type="pmid">4928532</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19431.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Detels</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Green</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Klausner</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Katzenstein</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Gaydos</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Handsfield</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Pequegnat</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Mayer</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Hartwell</surname>
                <given-names>TD</given-names>
              </name>
              <name>
                <surname>Quinn</surname>
                <given-names>TC</given-names>
              </name>
            </person-group>
            <article-title>The incidence and correlates of symptomatic and asymptomatic Chlamydia trachomatis and Neisseria gonorrhoeae infections in selected populations in five countries.</article-title>
            <source>Sex Transm Dis</source>
            <year>2011</year>
            <month>Jun</month>
            <volume>38</volume>
            <issue>6</issue>
            <fpage>503</fpage>
            <page-range>503-9</page-range>
            <pub-id pub-id-type="pmid">22256336</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19431.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <article-title>Pelvic inflammatory disease.</article-title>
            <source>Am Fam Physician</source>
            <year>2012</year>
            <month>Apr</month>
            <day>15</day>
            <volume>85</volume>
            <issue>8</issue>
            <fpage>797</fpage>
            <page-range>797-8</page-range>
            <pub-id pub-id-type="pmid">22534389</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19431.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kobayashi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kida</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Reactive arthritis: recent advances and clinical manifestations.</article-title>
            <source>Intern Med</source>
            <year>2005</year>
            <month>May</month>
            <volume>44</volume>
            <issue>5</issue>
            <fpage>408</fpage>
            <page-range>408-12</page-range>
            <pub-id pub-id-type="pmid">15942084</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19431.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schachter</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Grossman</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sweet</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Holt</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Jordan</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bishop</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Prospective study of perinatal transmission of Chlamydia trachomatis.</article-title>
            <source>JAMA</source>
            <year>1986</year>
            <month>Jun</month>
            <day>27</day>
            <volume>255</volume>
            <issue>24</issue>
            <fpage>3374</fpage>
            <page-range>3374-7</page-range>
            <pub-id pub-id-type="pmid">3712696</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19431.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tipple</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Beem</surname>
                <given-names>MO</given-names>
              </name>
              <name>
                <surname>Saxon</surname>
                <given-names>EM</given-names>
              </name>
            </person-group>
            <article-title>Clinical characteristics of the afebrile pneumonia associated with Chlamydia trachomatis infection in infants less than 6 months of age.</article-title>
            <source>Pediatrics</source>
            <year>1979</year>
            <month>Feb</month>
            <volume>63</volume>
            <issue>2</issue>
            <fpage>192</fpage>
            <page-range>192-7</page-range>
            <pub-id pub-id-type="pmid">440806</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19431.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kohlhoff</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Hammerschlag</surname>
                <given-names>MR</given-names>
              </name>
            </person-group>
            <article-title>Treatment of Chlamydial infections: 2014 update.</article-title>
            <source>Expert Opin Pharmacother</source>
            <year>2015</year>
            <month>Feb</month>
            <volume>16</volume>
            <issue>2</issue>
            <fpage>205</fpage>
            <page-range>205-12</page-range>
            <pub-id pub-id-type="pmid">25579069</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19431.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Workowski</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Bolan</surname>
                <given-names>GA</given-names>
              </name>
              <collab>Centers for Disease Control and Prevention</collab>
            </person-group>
            <article-title>Sexually transmitted diseases treatment guidelines, 2015.</article-title>
            <source>MMWR Recomm Rep</source>
            <year>2015</year>
            <month>Jun</month>
            <day>05</day>
            <volume>64</volume>
            <issue>RR-03</issue>
            <fpage>1</fpage>
            <page-range>1-137</page-range>
            <pub-id pub-id-type="pmid">26042815</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19431.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stamm</surname>
                <given-names>WE</given-names>
              </name>
              <name>
                <surname>Batteiger</surname>
                <given-names>BE</given-names>
              </name>
              <name>
                <surname>McCormack</surname>
                <given-names>WM</given-names>
              </name>
              <name>
                <surname>Totten</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Sternlicht</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kivel</surname>
                <given-names>NM</given-names>
              </name>
              <collab>Rifalazil Study Group</collab>
            </person-group>
            <article-title>A randomized, double-blind study comparing single-dose rifalazil with single-dose azithromycin for the empirical treatment of nongonococcal urethritis in men.</article-title>
            <source>Sex Transm Dis</source>
            <year>2007</year>
            <month>Aug</month>
            <volume>34</volume>
            <issue>8</issue>
            <fpage>545</fpage>
            <page-range>545-52</page-range>
            <pub-id pub-id-type="pmid">17297383</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19431.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rours</surname>
                <given-names>GI</given-names>
              </name>
              <name>
                <surname>Duijts</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Moll</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Arends</surname>
                <given-names>LR</given-names>
              </name>
              <name>
                <surname>de Groot</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Jaddoe</surname>
                <given-names>VW</given-names>
              </name>
              <name>
                <surname>Hofman</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Steegers</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Mackenbach</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Ott</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Willemse</surname>
                <given-names>HF</given-names>
              </name>
              <name>
                <surname>van der Zwaan</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Verkooijen</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>Verbrugh</surname>
                <given-names>HA</given-names>
              </name>
            </person-group>
            <article-title>Chlamydia trachomatis infection during pregnancy associated with preterm delivery: a population-based prospective cohort study.</article-title>
            <source>Eur J Epidemiol</source>
            <year>2011</year>
            <month>Jun</month>
            <volume>26</volume>
            <issue>6</issue>
            <fpage>493</fpage>
            <page-range>493-502</page-range>
            <pub-id pub-id-type="pmid">21538042</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
